Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 7/20 | 1.00 |
| ▸ | SLC1A1 | P43005 | 7/20 | 1.00 |
| ▸ | SLC1A3 | P43003 | 5/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 4/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039722 | 1.00 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL20838572 | 1.00 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL1039720 | 1.00 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL5324679 | 0.88 | GRIK1 (0.78) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL2267187 | 0.88 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL8764560 | 0.88 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL17874870 | 0.88 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL4379766 | 0.88 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL12611015 | 0.86 | CHRM1 (0.83) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL20838575 | 0.86 | SLC1A2 (1.00) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| CN-102408561-A | Segmented copolymer and its preparation method, and temperature sensitive type hydrogel | CHANGCHUN APPLIED CHEMISTRY | 2012-04-11 | — | — | CN | disclosed |
| WO-2007002469-A2 | THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-6939854-B2 | Peptide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-6846806-B2 | Peptide inhibitors of Hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | PRIESTLEY E SCOTT (DE) | 2004-07-29 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | SLC1A2 3427/4885SLC1A1 2630/4885SLC1A3 2604/4885 |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | VIP, PRSS1, CTSC | SLC1A2 4593/4885SLC1A1 3577/4885SLC1A3 3645/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | SLC1A2 4117/4885SLC1A1 3301/4885SLC1A3 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.